Table 2.
Clinical properties and laboratory findings in the study groups that were established by low density lipoprotein-cholesterol levelsa
| Group 1 (n=57) | Group 2 (n=143) | Group 3 (n=157) | p | |
|---|---|---|---|---|
| Age (months) | 165.5 (132–190) | 135.5 (105–157) | 144 (116–178) | <0.001 |
| Female/Male (n, %) | 30/27 (53/47) | 77/66 (54/46) | 92/65 (59/41) | 0.62 |
| BW (kg) | 70.6±25.5 | 62.9±20.7 | 65.4±20.7 | 0.08 |
| Height (cm) | 157.5 (139–166) | 150.5 (137–161) | 152 (141–161) | 0.07 |
| BMI (kg/m2) | 28.5 (24.2–32.4) | 26.5 (24.3–29.6) | 27.3 (24.6–30.3) | 0.39 |
| BWH (%) | 148 (128–172) | 150 (138–164) | 152 (129–162) | 0.07 |
| Glucose (mg/dL) | 85 (81–91) | 85 (81–90) | 84 (80–89) | 0.45 |
| Insulin (uU/mL) | 19.7 (10.6–26.1) | 16.1 (10.1–22.7) | 15.3 (10.6–25.3) | 0.67 |
| TC (mg/dL) | 111 (99–121) | 157 (141–174) | 202 (192–216) | 0,00 |
| TG (mg/dL) | 79.5 (50–110) | 93 (71–126) | 129 (96–187) | 0,00 |
| LDL-C (mg/dL) | 40 (35–53) | 46(40–53) | 45(39–52) | 0.20 |
| HDL-C (mg/dL) | 41 (18–78) | 62 (33–111) | 85 (43–144) | 0,00 |
| AST (U/L) | 24 (18.7–36) | 22 (18–27.2) | 22 (19–27) | 0.12 |
| ALT (U/L) | 21 (15–42) | 19 (15–25) | 18 (15–31) | 0.23 |
| fT4 (ng/dL) | 1.2 (1.12–1.32) | 1.26 (1.14–1.35) | 1.21 (1.12–1.33) | 0.42 |
| TSH (mIU/mL) | 2.8 (1.9–3.5) | 2.6 (1.9–3.6) | 2.8 (2.1–3.6) | 0.47 |
a: Data with normal distribution are expressed as mean±SD and the data that do not have a normal distribution are expressed as median (25–75th percentile) values. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BWH: Body weight-for-height; HDL-C: High-density lipoprotein-cholesterol; LDL-C: Low-density lipoprotein-cholesterol; NAFLD: Non-alcoholic fatty liver disease; TG: Triglyceride; fT4: Free t4; TSH: Thyroid-stimulating hormone; BW: Body weight; BMI: Body mass index